JAAD 12/23 Cutaneous tuberculosis. Part I: Pathogenesis, classification, and clinical features

JAAD 12/23 Cutaneous tuberculosis. Part II: Complications, diagnostic workup, histopathological features, and treatment

JAAD 11/23 Gaps in Medical Education Curricula on Skin of Color in Medical School, Residency, and Beyond Part 1

JAAD 11/23 Racial and Ethnic Disparities in Clinical Research and the Dermatology Workforce Part 2

JAAD 10/23 Implementing Patient Safety and Quality Improvement in Dermatology Part 1: Patient Safety Science

JAAD 10/23 Implementing Patient Safety and Quality Improvement in Dermatology Part 2: Quality Improvement Science

JAAD 09/23 Melanoma in Skin of Color: Part I. Epidemiology and clinical presentation

JAAD 09/23 Melanoma in Skin of Color: Part II. Racial disparities, role of UV, and interventions for earlier detection

JAAD 08/23 Part I: Cutaneous Manifestations of Cardiovascular Disease

JAAD 08/23 Part II Cutaneous Manifestations of Peripheral Vascular Disease

JAAD 07/23 Dermatology Workforce in the United States – Part 1: Overview, Transformations, and Implications

JAAD 07/23 Dermatology Workforce in the United States – Part 2: Patient Outcomes, Challenges, and Potential Solutions

JAAD 06/23 Immunotherapy for Keratinocyte Cancers. Part 1: Immune-Related Epidemiology, Risk Factors, Pathogenesis, and Immunotherapy Management of Keratinocytic Cancers

JAAD 06/23 Immunotherapy for Keratinocyte Cancers. Part 2: Identification and Management of Cutaneous Side Effects of Immunotherapy Treatments

JAAD 05/23 An Update on Viral Induced Cutaneous Lymphoproliferative Disorders. A Review from the Ibero-American Society of Dermatopathology (SILADEPA). CME Part I.

JAAD 05/23 An Update on EBV and HTLV-1 Induced Cutaneous Manifestations. A Review of the Ibero-American Society of Dermatopathology

JAAD 04/23 Skin disorders and interstitial lung disease. Part I. Screening, Diagnosis and Therapeutic Principles

JAAD 04/23 Skin disorders and interstitial lung disease: Part II. The spectrum of cutaneous diseases with lung disease association.

JAAD 03/23 Risk of melanoma and nonmelanoma skin cancer with immunosuppressants. Part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids

JAAD 03/23 Risk of melanoma and nonmelanoma skin cancer with immunosuppressants. Part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors

JAAD 02/23 Disorders of Hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders

JAAD 02/23 Disorders of Hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation

JAAD 01/23 Dysplastic Nevus Part I: Historical Perspective, Classification, and Epidemiology

JAAD 01/23 Dysplastic Nevus Part II: Dysplastic Nevi: Molecular/Genetic Profiles and Management